Do you want to read an article? Please log in or register.
Durvalumab After Chemoradiotherapy for Locally Advanced NSCLC: A Real-World Analysis Using a Nationwide Claims Database in Japan
Lung Cancer
Related content
Lung Cancer
Locally advanced NSCLC: overview of real-world pattern of recurrence in durvalumab era (LEOPARD trial)
Lung Cancer
Ciammella P, Iori F, Borghetti P, Galaverni M, Alì E, Tiseo M, Pagano M, Sepulcri M, Scotti V, GiajLevra N, Marcenaro M, Simoni N, Nardone V, Botti A, Cozzi S, Bruni A
doi: 10.1016/j.lungcan.2025.108718
RECOMMENDED
Lung Cancer
Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC
★ 1
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
ESMO Open
Girard N, Bar J, Baas P, Chouaid C, Christoph DC, Field JK, Fietkau R, Garassino MC, Garrido Lopez P, Gregorc V, Haakensen VD, Hiltermann TJN, Kao S, McDonald F, Mornex F, Moskovitz M, Peters S, Siva S, Solomon B, Qiao Y, Anand S, Chander P, Shcherbakova T, Diaz Perez I, Filippi AR
doi: 10.1016/j.esmoop.2026.106070
Lung Cancer
Advanced-stage ALK-positive non-small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database
Lung Cancer
Reale ML, Scattolin D, Vitale A, Passiglia F, Grisanti S, Macerelli M, Galetta D, Sini C, Minuti G, Citarella F, Roca E, Agustoni F, Dodi A, Cortinovis D, Belluomini L, Ricciardi S, Veccia A, Pizzutilo EG, Scotti V, Alì G, Mazzoni F, Russo A, Pignataro D, Bulotta A, Piovano P, Sergi C, Bettini A, Genova C, Pavan A, Soto Parra HJ, Ortega C, Pozzessere D, Vavalà T, Chiari R, Zannori C, D'Aveni A, Meoni G, Giannarelli D, Malapelle U, Novello S, Bria E, Pasello G
doi: 10.1016/j.lungcan.2025.108762
Lung Cancer
Real-world comparative effectiveness of sotorasib versus docetaxel monotherapy in second line and beyond for advanced or metastatic non-small cell lung cancer: A national database analysis from England
Lung Cancer
Karim N, Arnold K, Summers Y, Akram T, Trankov N, Vladimirova A, Chopra D, Mesa-Frias M, Waterhouse D, Stollenwerk B
doi: 10.1016/j.lungcan.2026.109469
COPD
Comparison of the Risk of Pneumonia Between Fluticasone Furoate/Umeclidinium/Vilanterol and Multiple-Inhaler Triple Therapy in Patients with COPD Using Health Insurance Claims Data: Final Analysis of Post-Marketing Database Surveillance in Japan
J Clin Med
Akiyama S, Oda K, Mizohata H, Sasakura N, Hashimoto K, Maruoka H
doi: 10.3390/jcm14134697
RECOMMENDED
Lung Cancer
Real-world survival outcomes of immune checkpoint inhibitor therapy after standard treatment failure in EGFR-mutated NSCLC: A nationwide cohort study
★ 1
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Lee J, Kim M, Han HJ, Kim S, Suh HS
doi: 10.1016/j.lungcan.2025.108682
Asthma
Real-World Safety and Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Asthma: Final Analysis of a Post-Marketing Surveillance in Japan
Adv Ther
Asai K, Morioka Y, Ito R, Komatsubara M, Maruoka H
doi: 10.1007/s12325-025-03421-2
RECOMMENDED
Lung Cancer
Real-World Clinical Outcomes and Treatment Patterns in Advanced/Metastatic EGFR-Mutant NSCLC After Progression on First-Line Osimertinib for French Patients
★ 1
Recommended by
Dr. med. Martin Frey, Faculty Member
Adv Ther
Girard N, Macouillard P, Byng D, Meng J, Coerts F, Hunter S, Struebing A, Xiong Y, Park S, Haq MI, Tymejczyk O, Chouaid C, Audigier-Valette C, Debieuvre D, Quantin X, Bosquet L, Pérol M
doi: 10.1007/s12325-025-03465-4
Lung Cancer
Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trial
Nat Cancer
Peters S, Tan DSW, Gerber DE, Urbanic J, Ramalingam S, Yu J, Xing L, Rittmeyer A, Ciuleanu TE, de Menezes J, Kim HR, Rojas C, Syrigos K, Hayashi H, Haridass A, Cortinovis D, Bruno D, Kimmich M, Calles A, Nathani R, Pudussery G, Yang L, De Ruysscher D
doi: 10.1038/s43018-026-01161-y